$2.67
-0.08 (-2.91%)
Open$2.75
Previous Close$2.75
Day High$2.79
Day Low$2.67
52W High$3.72
52W Low$1.70
Volume—
Avg Volume604.8K
Market Cap196.97M
P/E Ratio—
EPS$-1.58
SectorBiotechnology
Analyst Ratings
Strong Buy
13 analysts
Price Target
+520.6% upside
Current
$2.67
$2.67
Target
$16.57
$16.57
$14.06
$16.57 avg
$23.26
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 19.33M | 18.18M | 17.68M |
| Net Income | -947,103 | -802,247 | -886,084 |
| Profit Margin | -4.9% | -4.4% | -5.0% |
| EBITDA | -1,287,077 | -1,124,832 | -1,061,399 |
| Free Cash Flow | -739,760 | -479,993 | -441,081 |
| Rev Growth | +21.0% | +13.7% | -3.4% |
| Debt/Equity | 0.36 | 0.44 | 0.33 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $263.29 | -1.12% | 74.3 | 468.50B |
| AMGN | Amgen Inc | $423.64 | +1.32% | 25.1 | 219.78B |
| GILD | Gilead Sciences Inc | $151.28 | -0.61% | — | 185.02B |
| VRTX | Vertex Pharmaceuticals Inc | $526.73 | -0.18% | 30.5 | 134.17B |
| REGN | Regeneron Pharmaceuticals | $750.51 | -0.23% | 18.8 | 81.31B |
| ALNY | Alnylam Pharmaceuticals Inc | $254.07 | -0.51% | 41.4 | 33.44B |